drugset / Trial / NCT04973007
Comparison of Contrast Agents in Liver Magnetic Resonance (MR) for the Detection of Hepatic Metastases
Phase 4
Terminated
10 enrolled
University of Colorado, Denver
Bracco Diagnostics, Inc · collabNational Cancer Institute (NCI) · collab
RandomizedCrossoverSingle-blindDiagnostic
Summary
If an abbreviated hepatobiliary phase (HBP) protocol liver MR with gadobenate dimeglumine is shown clinically comparable to standard of care liver MR with gadoxetate disodium for detecting hepatic metastasis from colorectal cancer, its use will save time, cost, and patients' effort.
Timeline
- Start
- 2021-06-22
- Primary completion
- 2025-05-06
- Completion
- 2025-05-08
Outcome
Outcome not reported
Stopped (Enrollment): “Low Accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gadobenate dimeglumine | Diagnostic / imaging agent | — | — |
| Subject | Gadoxetate disodium | Diagnostic / imaging agent | — | — |